Axa
TXMD icon

Axa’s TherapeuticsMD TXMD Stock Holding History

Axa’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-91,387
Closed -$5.44M – 1326
2021
Q2 		$5.44M Sell
91,387
-42,766
-32% -$2.59M 0.02% 688
2021
Q1 		$8.99M Buy
134,153
+44,251
+49% +$3.46M 0.03% 544
2020
Q4 		$5.44M Buy
89,902
+22,140
+33% +$1.51M 0.02% 672
2020
Q3 		$5.35M Buy
67,762
+4,788
+8% +$382K 0.02% 602
2020
Q2 		$3.94M Buy
62,974
+387
+0.6% +$22.5K 0.02% 683
2020
Q1 		$3.32M Hold
62,587
– – 0.02% 625
2019
Q4 		$7.57M Hold
62,587
– – 0.03% 510
2019
Q3 		$11.4M Sell
62,587
-1,663
-3% -$234K 0.05% 433
2019
Q2 		$8.35M Buy
64,250
+8,475
+15% +$1.52M 0.03% 518
2019
Q1 		$13.6M Buy
55,775
+7,139
+15% +$1.89M 0.05% 387
2018
Q4 		$9.27M Buy
48,636
+19,371
+66% +$4.72M 0.04% 434
2018
Q3 		$9.6M Buy
29,265
+8,024
+38% +$2.46M 0.04% 491
2018
Q2 		$6.63M Hold
21,241
– – 0.03% 575
2018
Q1 		$5.17M Buy
+21,241
New +$5.96M 0.02% 641

Other funds holding TXMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Axa's TXMD Position: Q3 2021 in Review

Axa sold out of TherapeuticsMD (TXMD) in Q3 2021, closing a stake of 91,387 shares — an estimated $5.44M sold.

Axa first reported a position in TXMD in Q1 2018 and held it in 14 quarters. The position peaked at $13.6M in Q1 2019. 149 funds tracked by Wall St. Rank hold TXMD as of Q3 2021.

  • Axa reported no remaining TherapeuticsMD position as of Q3 2021 after selling out during the quarter.
  • Axa sold 91,387 TherapeuticsMD shares in Q3 2021, an estimated $5.44M.
  • Axa first reported a position in TherapeuticsMD in Q1 2018 and held it in 14 quarters.
  • Axa's TherapeuticsMD position peaked at $13.6M in Q1 2019.
  • 149 funds tracked by Wall St. Rank held TherapeuticsMD as of Q3 2021.

Based on Axa's 13F filing for Q3 2021, filed 15 Nov 2021.